Navigation Links
Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
Date:9/30/2009

either the cocaine or the methamphetamine trial. Furthermore, additional safety tests conducted in the methamphetamine trial revealed no brain or clinically significant cardiovascular abnormalities in any subject. Finally, no significant differences were found in the rates of adverse events between the CPP-109 and placebo treated subjects in either study.

Frank Vocci, Ph.D., President, Friends Research Institute and a former Director of the Division of Pharmacotherapies and Medical Consequences of the National Institute on Drug Abuse (NIDA), who participated in the experts panel, stated, "Based on expanded analyses from the Catalyst trial, compliant participants receiving vigabatrin tended to have fewer cocaine use days and generally lower cocaine metabolite levels in their urine than non-compliers. After reviewing these results and those from the recently published double-blind, placebo controlled trial conducted by Dr. Jonathan Brodie and his colleagues in Mexico, I believe CPP-109's favorable safety profile and the statistically significant 3.5 times increase in the achievement of abstinence with vigabatrin treatment that he reported, strongly support continuing the clinical development program for vigabatrin."

Patrick J. McEnany, Chief Executive Officer of Catalyst, stated, "There remains a tremendous unmet medical need for cocaine and methamphetamine addicted patients, and we believe a safe and effective patient-specific treatment may generate considerable interest among regulatory authorities, patients, physicians, investors and potential strategic partners. Our next step will be to present our findings to NIDA, the investment community, and potential strategic partners to obtain the funding to conduct additional clinical trials. We remain optimistic about the prospects for CPP-109 going forward and we are committed to aggressively pursuing our two primary objectives: (i) the continued development of CPP-109 towards a pivotal Phase
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
2. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
3. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
6. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
7. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
8. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
9. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
10. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes ... JIN Co., Ltd. will launch JINS MEME "ACADEMIC PACK" ... yen or $5,000 (without tax /including two pairs of JINS ... a dedicated solution of "JINS MEME" to academic researchers, and ... generated by electrooculography and six-axis sensors without API. (*Physiological data ...
(Date:11/26/2014)... 2014  Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... On Tuesday, December 2, the company will ... Healthcare Conference.  D. Keith Grossman , President and ... company beginning at 11:30 a.m., Eastern Standard Time (8:30 ...
(Date:11/26/2014)... 2014   Royal Philips (NYSE: ... availability of its portfolio of diagnostic X-ray ... Opta[i] , ProGrade and PrimaryDiagnost[ii]. With new releases ... the U.S., and availability of all these solutions ... customers innovative solutions designed to meet the needs ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Thoratec Announces Presentations At Investor Conferences For December 2014 2Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
... in Management of Transplant Recipients with Cancer, ... in post-transplant patients with cancer is challenging.,Clinicians must ... while,simultaneously monitoring the impact of chemotherapeutic agents on ... management of such patients will be,presented today at ...
Cached Medicine Technology:Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity 2
(Date:11/27/2014)... "As a nurse I see patients every ... incontinence," said an inventor from Whiting, N.J. "I put ... to prevent leakage and keep them dry and comfortable." ... This prevents stains on pants, skirts and bottoms, which ... that the individual has time to get to the ...
(Date:11/27/2014)... 27, 2014 Nearly 1,100 Risperdal ... in a consolidated litigation now underway in Pennsylvania ... Documents recently updated in the Philadelphia Court of ... state proceeding, all of which involve a drug ... psychiatric conditions. Many of the cases in this ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 ... a second language, new research suggests. But anyone who tries ... brain boost, the small study finds. The brain ... Ping Li, co-director of the Center for Brain, Behavior and ... Li said, that "the brain networks of the more successful ...
(Date:11/27/2014)... News) -- Most babies and young children don,t need ... and Drug Administration says. Over-the-counter (OTC) cold and ... than 2 because they could cause serious and potentially ... average about three colds a year, but children get ... might want to give them pain relievers, decongestants and ...
(Date:11/27/2014)... Thompson HealthDay Reporter WEDNESDAY, ... appears to be safe and produces an immune system response ... early clinical trial results reported by the U.S. National Institutes ... trial for the vaccine paves the way for field-testing it ... Leone as early as January, said Dr. Anthony Fauci, director ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3
... Roche Pharmaceuticals has granted a sub-license to Indian firm Hetero ... is the only drug known so far to have any ... virus. ,Hetero is based at Hyderabad and ... distributed across South East Asia and Africa. Commenting on the ...
... gearing up worldover, as the australian health minister ... be provided to all patients visiting queensland// hospital ... smoking following which the Australian Competition and Consumer ... sponsor anti-smoking advertising. ,Cigaretter manufacturers in ...
... and Resorts has banned smoking in the rooms, restaurants, bars ... Canada and the Caribbean from January 2006//., ,Guests will ... outdoor areas. , ,Westin said research among its customers ... room. , ,"Nobody likes to walk into a smoky ...
... has revealed that routine chest X-rays may serve to identify ... 172,000 Americans // are expected to be diagnosed with lung ... as this disease is invariably detected late. ,Earlier ... tumors, or patients were put through risky surgery as a ...
... and Finch showed the effect of childhood infections and ... diseases // . ,They collected mortality data ... and Switzerland from different years but ending with individuals ... was an important factor in treating childhood illness. ...
... Scientists in Scotland have discovered that an ordinary kitchen ... superbug, which is capable of resisting many // antibiotics. ... brand of the kitchen-scouring pad alone contains the cure ... according to reports can be grown on one particular ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: